Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?
Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
A 6.20% dividend yield in big pharma usually means one of two things: a mispriced income stock or a payout the market has already begun to doubt. Pfizer (NYSE:PFE | PFE Price Prediction) trades at $27.67 and the payout’s own behavior is the tell.
Raise Pattern: A Streak That Just Went Quiet
Pfizer had lifted its quarterly dividend every year for more than a decade, moving from $0.18 in 2010 to $0.42 across 2024, with the annual bump landing on the January payment. That January step-up happened on schedule at the start of 2025, taking the quarterly to $0.43.
Then the pattern broke. The January 2026 ex-dividend payment came in at $0.43, matching the prior four quarters instead of rising. The May and July 2026 declarations were also $0.43, and the next payment, dated September 1, 2026, holds the same rate. The streak has stalled while the payout remains intact.
Is the Check Funded?
On adjusted earnings, coverage is comfortable. Pfizer reaffirmed 2026 adjusted diluted EPS of $2.80 to $3.00 against a run-rate $1.72 annual payout. Q1 2026 adjusted EPS of $0.75 beat consensus and marked a fifth consecutive quarter above estimates. Cash outflow is real: $2.4 billion in dividends went out in Q1 alone, and $9.8 billion for full-year 2025.
Management has removed the other lever. Pfizer completed no buybacks in 2025 and anticipates none in 2026, even with $3.3 billion of authorization sitting unused. Leverage ended Q2 2026 at 2.7 times. On the August 4, 2026 call, Cecile Guégan, incoming interim CFO, said Pfizer would keep “maintaining, and over the long term, growing the dividend.” Chairman and CEO Albert Bourla went further:
“We feel extremely confident that we will, even the most stretched scenarios that we are running, we will be able to maintain our dividend. The dividend will be maintained and eventually after the LOE period will start again growing it.”
Peers Aren’t Fighting the Same Backdrop
Contrast the freeze with two peers. Merck (NYSE:MRK) lifted its quarterly from $0.81 to $0.85 starting with the December 2025 ex-date. Bristol-Myers Squibb (NYSE:BMY) nudged its payout from $0.62 to $0.63 with the January 2026 ex-date. Both raised. Pfizer did not.
The pressures behind that pause are visible in the mix. Comirnaty fell 59% and Paxlovid fell 62% in Q1 2026, with roughly $1.5 billion in additional generic and biosimilar headwind guided for the year. Offsetting that: launched and acquired products grew 22% operationally, and Vyndamax exclusivity now runs to June 2031.
Growing or Frozen?
The 6.20% yield is real, adjusted-earnings coverage is intact, and management has publicly committed to defending it. For now, income holders are collecting a maintained dividend at the current rate. Until the payout ticks higher again, Pfizer remains a yield story.
A double-digit yield often signals a cut coming, and even a 6% payer with a frozen streak deserves a second look. We laid out the seven warning signs to watch in a free dividend trap guide.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
